New pill shows promise for Hard-to-Treat leukemias
NCT ID NCT04139434
First seen Jan 27, 2026 · Last updated Jun 05, 2026 · Updated 25 times
Summary
This early-phase trial tested an experimental pill called LP-108, given alone or with another drug (azacitidine), in 32 adults whose myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia had returned or stopped responding to prior treatments. The main goals were to find the safest dose and understand how the drug moves through the body. While the study looked at whether the cancer shrank, it was too small and early to draw firm conclusions about effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital San Pedro de Alcántara
Cáceres, Cáceres, 10003, Spain
-
Institut Català d'oncologia - ICO Badalona
Badalona, Barcelona, 08916, Spain
-
Instituto de Investigación Sanitaria La Fe
Valencia, Valencia, CP 46026, Spain
-
MD Anderson Cancer Center
Huston, Texas, 77030, United States
-
Ohio State Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Cincinnati
Cincinnati, Ohio, 45221, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.